Johnson & Johnson (JNJ) Declares $0.84 Quarterly Dividend; 2.5% Yield

Wall Street ends flat; Netflix jumps after the bell

July 17, 2017 7:24 AM EDT

By Rodrigo Campos and Kimberly Chin

NEW YORK (Reuters) - U.S. stocks closed little changed in low volume on Monday as gains in utilities and consumer stocks offset declines in healthcare, with earnings news filtering out winners and losers across the board.

BlackRock shares (NYSE: BLK) fell 3.1 percent to $424.63 after the world's biggest asset manager's quarterly profit came in below expectations.

After the closing bell, Netflix (NASDAQ: NFLX) shares jumped 8.5 percent to $175.45 following... More

Johnson & Johnson (JNJ): Looking Through A Tough Quarter To Catalysts, Raising PT - Jefferies

July 14, 2017 8:19 AM EDT

Jefferies analyst, Jeffrey Holford, reiterated his Hold rating on the shares of Johnson & Johnson (NYSE: JNJ) and raised his price target to $145 from $140 ahead of what's likely to be a tough quarter. The analyst is estimating Q2'17E revenue of $18.8bn which is... More

Johnson & Johnson (JNJ) Janssen Gains FDA Approval for Plaque Psoriasis Treatment TREMFYA

July 13, 2017 4:12 PM EDT

Johnson & Johnson's (NYSE: JNJ) Janssen Biotech, Inc.(Janssen) announced today that the U.S. Food and Drug Administration (FDA) has approved TREMFYA (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. TREMFYA is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine that plays a key role in plaque psoriasis. Approval comes after an expedited regulatory review following application of an FDA Priority Review Voucher. TREMFYA is administered as a 100 mg subcutaneous injection every eight weeks, following two... More